As Sanofi prunes pipeline, ex-Alexion crew at Rallybio picks up anemia drug
More than a year after it bought Kymab for $1.5 billion, Sanofi is getting rid of a preclinical program that came with the deal.
Sanofi has out-licensed its KY1066 antibody to New Haven, CT-based Rallybio who has redubbed it RLYB331. The deal saw Rallybio make an upfront cash payment of $3 million to Sanofi in addition to promising development and commercial milestones and mid to high single-digit royalties on net sales.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.